The product designated L-Cysteine HCl Mono amino acids and derivatives Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is a compendial-grade L-cysteine hydrochloride monohydrate, CAS 7048-04-6, molecular formula C3H7NO2S·HCl·H2O, and molecular weight 175.63 g/mol. The material is released as a white or almost white crystalline powder with assay, optical rotation, loss on drying, residue on ignition, chloride identity, related-substance, and elemental impurity controls aligned to current USP-NF, Ph.Eur., and JP monographs. As the hydrochloride salt of a sulfur-containing amino acid, it provides the free thiol functionality required for sulfhydryl–disulfide exchange, prodrug conjugation, antioxidant stabilization, and parenteral nutrition compounding. The API is assigned to multi-route use: direct compression and wet granulation for tablets, capsule filling, powder or granule sachets, and sterile injectable processing where the parenteral grade is specified. The hydrochloride counterion increases aqueous solubility relative to L-cysteine base and produces acidic solution pH values; buffering to physiological pH is therefore a finished-formulation requirement for injection. The product is differentiated from L-cystine, N-acetyl-L-cysteine, S-carboxymethyl-L-cysteine, and related amino acid derivatives by counterion chemistry, thiol availability, aqueous solubility, and route-specific regulatory filing status.

What Specification Set Governs L-Cysteine HCl Monohydrate as a Multi-Route API?

The release and stability specification is not a single universal value set; it is layered by dosage-route risk. For oral solid-dose grades, the core specification includes appearance, identification by infrared absorption against a reference standard, chloride identification, assay, loss on drying, specific optical rotation, residue on ignition, and limit tests for iron, arsenic, and sulfated ash. For injectable grades, additional controls for bacterial endotoxins, microbial enumeration, and subvisible particulate matter are agreed between the API manufacturer and the finished-product marketing authorization holder. The table below lists release parameters commonly used in API certificates of analysis; the values shown are compendial alignment thresholds, not maximum daily dose allowances.

ICH Q3D elemental impurities are managed through a route-specific risk assessment; oral and parenteral products require separate permitted daily exposure calculations for arsenic, cadmium, lead, mercury, and catalyst residues. Residual solvents from the routine synthesis route are typically limited to Class 3 solvents with no individual residual above 0.5% w/w unless an individual solvent requires tighter control. The glass transition or melting event is not a discriminating release test; L-cysteine hydrochloride monohydrate decomposes before or near melting, so identity is confirmed spectroscopically and by chloride, while purity is controlled through assay and related substances rather than thermal transition temperature.

When Injection Grade API Is Selected for Terminal Sterilization or Aseptic Processing

When the API is designated for injectable use, the formulation route, not the API monograph alone, determines the critical process boundary. Aqueous solutions of L-cysteine hydrochloride monohydrate are acidic; the free thiol is stabilized at low pH, but terminal sterilization by autoclave can accelerate oxidation to L-cystine and generate disulfide-linked impurities. Aseptic filtration through 0.22 µm membranes is therefore more commonly used for final sterilization when the drug product is heat-labile. If terminal sterilization is used, solution hold times, headspace oxygen, and cooling ramp rates must be qualified with assay and impurity profiles. The API is freely soluble in water; dissolution for parenteral use is carried out in water for injection at 2–8°C under nitrogen overlay to reduce oxygen ingress. The solution is typically neutralized with sodium hydroxide to a target pH between 5.0 and 7.0 before further processing, but the exact pH is formulation-specific because thiol oxidation, glass delamination risk, and active stability shift with pH and buffer species.

Compatibility with primary packaging is a release and stability variable. Type I glass vials with low extractable tungsten and sulfur-treated rubber closures have been used; headspace residual oxygen should be below 2% v/v after nitrogen flushing for oxygen-sensitive formulations. The API itself is not a sterile product unless contracted as sterile API; non-sterile injectable-grade API requires sterile filtration of the compounded solution. For lyophilized products, the acidic pH of the API can be adjusted with mannitol or trehalose bulking agents before drying; eutectic collapse is minimized by controlled nucleation or annealing. Published data for L-cysteine HCl monohydrate-specific lyophilization cycles is limited; cycle development must use differential scanning calorimetry and freeze-drying microscopy to determine critical formulation collapse temperatures.

Oxidative incompatibilities are operationally significant. Strong oxidizers, peroxide-containing excipients, ferric ion, and alkaline conditions accelerate thiol oxidation to L-cystine. Aldehyde-functional impurities or reducing sugars may react with the free thiol, so aldehyde-containing tablet excipients require careful compatibility screening. In liquid processing, stainless steel 316L is generally acceptable for short-term acidic holds, but surface passivation and extractable testing must be qualified for the specific hold time and temperature. The thiol pKa of cysteine is approximately 8.3; during pH neutralization the thiolate becomes increasingly oxidation-prone, which is why nitrogen blanketing and antioxidant loading are evaluated when finished parenteral pH is above 6.0.

Tabletting, Capsule Filling, and Granulation Behaviour at Production Scale

Dry-flow data from production-scale oral solid-dose handling indicate that the crystalline powder can be compacted directly at rotary tablet press speeds typical of forced-feed machines when the particle size distribution is controlled and a flow aid is added. The bulk and tapped-density ratio of the lot is measured by USP <616>; compressibility index values above 25 may require precompaction or granulation. For capsule filling, dosator and tamping-pin machines produce acceptable weight variability when the API is blended with a carrier such as lactose monohydrate or microcrystalline cellulose and the blend loss on drying is below 1.0% after blending. Wet granulation is used for formulations requiring higher drug load; the API is dry-mixed with intragranular excipients, then granulated with purified water or a binder solution such as polyvinylpyrrolidone. The wet mass should not be held at elevated temperature because the thiol oxidizes more quickly in moist alkaline environments; granule drying in a fluid-bed dryer with inlet air dew point below 10°C and product temperature not exceeding 50°C is used when thiol stability is critical.

Direct compression with L-Cysteine HCl Mono has a known processing limitation: at high tablet weight fractions, the salt can adhere to punch faces under low lubricant conditions. Magnesium stearate at 0.5–1.0% w/w is added in the final blending step; extended lubricant mixing beyond 5 min can reduce tensile strength. This behavior is not specific to L-cysteine hydrochloride but is common for crystalline amino acid salts with acidic surface pH. A regular milled grade for solid oral forms may control D90 at or below 150 µm and D50 in the 50–90 µm range, but the exact particle size specification is agreed per dosage form and is not interchangeable between tablet and capsule products. High-shear granulation torque endpoints are formulation-dependent; end-point values are selected using power consumption or impeller torque values from developmental batches, and the same target is then transferred to production equipment with geometric correction. Since the API is acidic and water-soluble, tablet cores containing high load can create a locally acidic dissolution environment; enteric coating performance and pH-sensitive release modifiers must be evaluated in development rather than assumed from excipient data alone.

Differentiation from other cysteine derivatives is governed by counterion chemistry and end-use compatibility. L-cysteine hydrochloride monohydrate is the salt form; it provides higher water solubility than L-cysteine base and is the preferred starting material for injectable formulations because clear concentrated solutions can be prepared without heating. L-cysteine base has a lower chloride burden and may be selected when sodium or chloride intake is constrained, but its oxidative stability and solubility profile differ. N-acetyl-L-cysteine carries the acetyl group on the thiol and cannot be substituted for L-cysteine HCl without reformulation and bioequivalence bridging. L-cystine is the oxidized dimer and is not functionally interchangeable with the reduced thiol form. The table below summarizes route and handling attributes for three commonly compared derivatives.

The monohydrate water content is not an impurity; it is part of the crystal lattice. Loss on drying outside 8.0–12.0% may indicate exposure to high humidity or loss of lattice water during improper storage. Closed containers with desiccant are used for oral grades; injectable grade is subdivided in low-humidity areas and may be double bagged with nitrogen. The product should be stored at controlled room temperature; prolonged storage above 25°C or under light increases the rate of thiol oxidation. The API is incompatible with strong oxidizers, peroxide-containing excipients, and oxidizing metal ions such as ferric ion. Because the aqueous solution is acidic, contact with certain metals may generate extractable contamination in holding tanks; stainless steel 316L is generally acceptable for short-term processing, but passivation and surface finish must be qualified.

Dissolution testing in pH-shift media should account for the acidic API. In pH 1.2 media, the salt dissolves quickly and may contribute to an acidic microenvironment; in pH 4.5 and 6.8 buffers, thiol oxidation can occur during the test, so oxygen-depleted or antioxidant-containing media may be needed for discriminatory stability-indicating release. The label claim of anhydrous L-cysteine HCl is calculated on the dried basis; if the formulation contains the monohydrate, the molecular weight correction must be applied before calculating salt-free cysteine equivalents in the finished product specification.